title: Characteristics and mortality among hospitalized patients treated with intramuscular antipsychotics: analysis of a United States hospital database.
abstract: Mortality rates across matched cohorts of hospitalized patients treated with IM olanzapine, haloperidol, and/or ziprasidone in a hospital database were compared. Using propensity score matching, matched cohorts of IM olanzapine- (N=2,984) and IM haloperidol-treated patients (N=2,984) and IM olanzapine- (N=2,876) and IM ziprasidone-treated patients (N=2,876) were obtained. The study outcome was in-hospital death within 2 days of administering IM antipsychotic. Incidence of death was not statistically different between olanzapine-ziprasidone cohorts (OR=1.21, 95% CI 0.92-1.59). The olanzapine cohort demonstrated a significantly lower death incidence than the haloperidol cohort (OR=0.73, 95% CI 0.57-0.93; p=.011). The results suggest that patients treated with IM olanzapine do not have a significantly greater risk of death than patients treated with IM haloperidol or IM ziprasidone.
authors.affiliation: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. kholdridge@lilly.com
authors.forename: Karen C
authors.initials: KC
authors.lastname: Holdridge
authors.forename: Sebastian
authors.initials: S
authors.lastname: Sorsaburu
authors.forename: John P
authors.initials: JP
authors.lastname: Houston
authors.forename: William
authors.initials: W
authors.lastname: Saunders
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects*; D015331:Cohort Studies; D016208:Databases, Factual; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects*; D017052:Hospital Mortality; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D000077152:Olanzapine; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects*; D014481:United States; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; D001569:Benzodiazepines; C092292:ziprasidone; D006220:Haloperidol; D000077152:Olanzapine